What have we learnt from Vioxx?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 17235089.
- Also identified by PMC identifier 1779871.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for compensation. But researchers and journals can still benefit from this case if they learn from the mistakes, write <b>Harlan Krumholz and colleagues</b>
Medical subject headings
- Cardiovascular Diseases
- Compensation and Redress
- Cyclooxygenase 2 Inhibitors
- Drug Industry
- Lactones
- Sulfones